SELENOP and metabolic syndrome: The levels of SELENOP in the MetS patients were lower than those in the controls (SMD = −0.48, 95% CI: −0.65 to −0.30, I2 = 5.6%, n = 8), while the levels of SELENOP in the patients with other diseases were not different from those in the controls, respectively (Figure 2).